S63845: Selective Small Molecule MCL1 Inhibitor for Apoptosis Research

Executive Summary: S63845 is a small molecule inhibitor with sub-nanomolar affinity (KD = 0.19 nM) for the anti-apoptotic protein MCL1, a key BCL-2 family member involved in mitochondrial apoptosis regulation (APExBIO). It disrupts MCL1-BAK/BAX interactions, activating caspase-dependent apoptosis in MCL1-dependent cancer cells (König et al., 2024). S63845 shows strong efficacy against multiple myeloma, lymphoma, chronic and acute myeloid leukemia cell lines, with IC50 values in the nanomolar to sub-micromolar range (Pha-793887.com). In vivo, it induces dose-dependent tumor regression in xenograft models (>100% maximal inhibition). S63845 is insoluble in water but highly soluble in DMSO and methanol for research use (APExBIO).

Biological Rationale

Apoptosis resistance is a hallmark of cancer, enabled by upregulation of anti-apoptotic proteins, including MCL1 (Myeloid Cell Leukemia 1), a BCL-2 family member (König et al., 2024). MCL1 inhibits mitochondrial outer membrane permeabilization by sequestering pro-apoptotic BAK and BAX, thus blocking cytochrome c release and subsequent caspase activation. Elevated MCL1 correlates with poor prognosis in hematological and some solid tumors, and confers resistance to chemotherapy (Survivin.net). Targeting MCL1 is a validated approach for restoring apoptosis sensitivity.

Mechanism of Action of S63845

S63845 is a small molecule that selectively binds human MCL1 with a dissociation constant (KD) of 0.19 nM and an inhibition constant (Ki) <1.2 nM (APExBIO). It competitively inhibits the binding of BAK and BAX to MCL1, releasing these pro-apoptotic proteins to induce mitochondrial outer membrane permeabilization (MOMP). This triggers cytochrome c release, caspase activation, PARP cleavage, and phosphatidylserine exposure, culminating in apoptosis of MCL1-dependent cancer cells (König et al., 2024). The specificity of S63845 for MCL1 over BCL-2 and BCL-XL mitigates off-target effects and enhances its utility as a tool compound for dissecting mitochondrial apoptotic pathways (Pha-793887.com).

Evidence & Benchmarks

• S63845 binds human MCL1 with KD = 0.19 nM at pH 7.4, 25°C (APExBIO, product data).
• Demonstrates IC50 values from nanomolar to sub-micromolar (e.g., 6–290 nM) for inducing apoptosis in multiple myeloma, lymphoma, chronic and acute myeloid leukemia cell lines (König et al., 2024).
• In xenograft models (H929 and AMO1 multiple myeloma), intravenous S63845 leads to dose-dependent tumor growth inhibition, up to 100% maximal inhibition and complete remission in a subset of animals (APExBIO).
• Induces mitochondrial apoptosis evidenced by BAX/BAK activation, cytochrome c release, and caspase-dependent PARP cleavage in cell-based assays (Pha-793887.com).
• Combination of S63845 with TRAIL or c-FLIP inhibitors enhances apoptotic cell death in PDAC and AML models (König et al., 2024).

For additional mechanistic details and recent advances in combinatorial strategies, see the article "S63845 and the Dual Targeting of Apoptosis Pathways in Cancer", which is extended here with updated benchmarks and translational context.

Applications, Limits & Misconceptions

S63845 is primarily used in academic and translational research to probe mitochondrial apoptosis, validate MCL1 as a therapeutic target, and develop combinatorial anti-cancer strategies. Its high selectivity makes it suitable for dissecting BCL-2 family network dependencies in hematological malignancies and select solid tumors (Survivin.net).

Common Pitfalls or Misconceptions

• Not active against all solid tumors: Efficacy is limited in cancers not primarily dependent on MCL1 for survival; resistance may occur via upregulation of BCL-2 or BCL-XL (Cy7-5-Maleimide.com).
• Not a clinical drug: S63845 is for research use only, not for diagnostic or therapeutic purposes (APExBIO).
• Solubility limitations: Insoluble in water; must be prepared in DMSO or methanol, and improper handling can affect reproducibility.
• Apoptosis pathway specificity: Does not directly activate extrinsic (death receptor-mediated) apoptosis; its main effect is via intrinsic/mitochondrial pathways.
• Degradation risk: Stock solutions degrade if not stored below -20°C and protected from repeated freeze-thaw cycles.

Workflow Integration & Parameters

S63845 (SKU: A8737) is supplied as a lyophilized powder by APExBIO. For experimental use, prepare stock solutions in 100% DMSO (≥41.45 mg/mL), optionally warming and sonicating to facilitate dissolution (product page). For cell-based assays, dilute stocks to working concentrations (typically 1 nM–10 μM) in culture medium containing <0.1% DMSO. For in vivo studies, dissolve in DMSO and further dilute in vehicle suitable for intravenous administration. Store stock solutions at -20°C, minimizing freeze-thaw cycles to preserve activity. S63845 is compatible with caspase-dependent apoptosis assays, mitochondrial membrane potential measurements, and BAX/BAK translocation studies. For detailed mechanistic experimentation and dual pathway modulation, consult this resource, which this article updates with validated workflow parameters.

Conclusion & Outlook

S63845 is a reference MCL1 inhibitor for studying mitochondrial apoptosis and modeling anti-cancer strategies in MCL1-dependent malignancies. Its high affinity, selectivity, and robust in vivo efficacy have established it as a pivotal tool for dissecting BCL-2 family signaling and combinatorial apoptosis modulation (König et al., 2024). As research expands to dual targeting of apoptosis pathways, S63845 will remain central to preclinical exploration and translational innovation. For ordering or detailed technical specifications, refer to the S63845 APExBIO product page. For advanced combinatorial strategies and translational guidance, see this recent review, which we extend here with new experimental data and workflow best practices.